CAMBRIDGE, Mass., June 01, 2024 Cullinan Therapeutics, Inc. , a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced positive initial data in.
Cullinan Therapeutics, Inc. announced positive initial data in patients receiving zipalertinib after prior treatment with amivantamab enrolled in its pivotal Phase 2b REZILIENT1 clinical trial. As of.
Zai Lab Limited (NASDAQ:ZLAB – Get Free Report) shares gapped down prior to trading on Wednesday . The stock had previously closed at $18.46, but opened at $17.73. Zai Lab shares last traded at $17.83, with a volume of 35,690 shares. Analyst Upgrades and Downgrades Separately, Citigroup reduced their target price on Zai Lab from […]
Baron Funds, an investment management company, released its “Baron Emerging Markets Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here.
Zai Lab begins topical IL-17 trial for mild to moderate psoriasis healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.